Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Dantari, Inc. logo — company profile

Dantari, Inc.

Founded 2018 United States Thousand Oaks, United States 7 employees Series A Total: $47.00M Life Sciences

General Information

Company Name Dantari, Inc.
Founded Year 2018
Location United States Thousand Oaks, United States
Employees 7
Industries Life Sciences
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Dantari, Inc.. To contact Dantari, Inc., visit dantari.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Dantari, Inc.

Dantari, Inc. is a clinical stage biotechnology company founded in 2018. The company is dedicated to developing groundbreaking therapies for the treatment of cancer and other serious diseases. Dantari recently secured a substantial $47.00M Series A investment on 08 December 2022. The investment was led by prominent investors including Corner Ventures, Alexandria Venture Investments, CalTech, and Westlake Village BioPartners. Headquartered in the United States, Dantari, Inc. is poised to make significant strides in the biotechnology industry.

Taxonomy: clinical stage, therapies, cancer treatment, pharmaceutical platform, drug development, central nervous system, small molecule therapeutics, large molecule therapeutics, blood-brain barrier, clinical improvement, medical breakthrough, innovation

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $47.00M 4
Corner Ventures Alexandria Venture Investments CalTech
Corner Ventures, Alexandria Venture Investments +2
08 Dec 2022
Seed Round Undisclosed 2
Corner Ventures Westlake Village BioPartners
Corner Ventures, Westlake Village BioPartners
26 Apr 2021

Dantari, Inc. Alternatives & Competitors

View All Alternatives
Dantari, Inc. vs
Allyx Therapeutics
Allyx Therapeutics United States

Protecting Synapses and Reversing Neurodegeneration

Venture round
5 employees
Biotechnology, Health Care
Dantari, Inc. vs
Aliada Therapeutics
Aliada Therapeutics United States

Beyond boundaries: Crossing the blood-brain barrier to create the next generation of central nervous...

Venture round
26 employees
Biotechnology, Health Care
Dantari, Inc. vs
HepaRegeniX GmbH
HepaRegeniX GmbH Germany

Unlocking liver regeneration - delivering recovery

15 employees
Biotechnology, Health Care
View all alternatives

FAQ About Dantari, Inc.

Dantari is a clinical stage biotechnology company committed to creating breakthrough therapies for the treatment of cancer and other serious diseases.
Dantari, Inc. was founded in 2018.
Dantari, Inc. is headquartered in Thousand Oaks, United States.
Dantari, Inc. operates in Life Sciences. Its work centres on clinical stage, therapies, cancer treatment and pharmaceutical platform.
Dantari, Inc. has approximately 7 employees.
Dantari, Inc. has completed 2 funding rounds, raising a total of $47.00M. The latest funding stage is Series A.
Top alternatives and competitors to Dantari, Inc. include Allyx Therapeutics, Aliada Therapeutics, HepaRegeniX GmbH, Proniras Corporation, Leap Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Dantari, Inc. and Allyx Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Dantari, Inc., https://bouncewatch.com/company/dantari-inc, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes